

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI598885

|                                   |   |
|-----------------------------------|---|
| <b>SUBMISSION TYPE:</b>           | NEW ASSIGNMENT                                |
| <b>NATURE OF CONVEYANCE:</b>      | ASSIGNMENT                                    |
| <b>CONVEYING PARTY DATA</b>       |   |
| <b>Name</b>                       | <b>Execution Date</b>                         |
| COHERUS BIOSCIENCES, INC.         | 06/26/2024                                    |
| <b>RECEIVING PARTY DATA</b>       |   |
| <b>Company Name:</b>              | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. |
| <b>Street Address:</b>            | 16 Xuefu Road                                 |
| <b>Internal Address:</b>          | High&New Tech Development Zone                |
| <b>City:</b>                      | Nanjing                                       |
| <b>State/Country:</b>             | CHINA   |
| <b>Postal Code:</b>               | 210061  |
| <b>PROPERTY NUMBERS Total: 23</b> |   |
| <b>Property Type</b>              | <b>Number</b>                                 |
| <b>Application Number:</b>        | 17608204                                      |
| <b>Patent Number:</b>             | 11583584                                      |
| <b>Patent Number:</b>             | 11576971                                      |
| <b>Patent Number:</b>             | 11071782                                      |
| <b>Patent Number:</b>             | 11396540                                      |
| <b>Patent Number:</b>             | 10435464                                      |
| <b>Patent Number:</b>             | 11229702                                      |
| <b>Patent Number:</b>             | 10772959                                      |
| <b>Patent Number:</b>             | 10772960                                      |
| <b>Patent Number:</b>             | 10799585                                      |
| <b>Patent Number:</b>             | 10786566                                      |
| <b>Patent Number:</b>             | 10780163                                      |
| <b>Patent Number:</b>             | 9707293                                       |
| <b>Patent Number:</b>             | 9770507                                       |
| <b>Patent Number:</b>             | 9731009                                       |
| <b>Patent Number:</b>             | 9782480                                       |
| <b>Patent Number:</b>             | 9737600                                       |
| <b>Patent Number:</b>             | 9731008                                       |
| <b>Patent Number:</b>             | 9724415                                       |

| Property Type  | Number  |
|----------------|---------|
| Patent Number: | 9757454 |
| Patent Number: | 9789185 |
| Patent Number: | 9808525 |
| Patent Number: | 9724414 |

#### CORRESPONDENCE DATA

**Fax Number:** 3129130002

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** (312)913-0001

**Email:** docketing@mbhb.com, alvarez@mbhb.com

**Correspondent Name:** Jill Alvarez

**Address Line 1:** McDonnell Boehnen Hulbert & Berghoff LLP

**Address Line 2:** 300 S. Wacker Drive

**Address Line 4:** Chicago, ILLINOIS 60606

**ATTORNEY DOCKET NUMBER:** 24-1371-WO-US

**NAME OF SUBMITTER:** Jill Alvarez

**SIGNATURE:** Jill Alvarez

**DATE SIGNED:** 10/31/2024

#### Total Attachments: 18

source=Patent Assignment (Coherus to HKF)\_Redacted#page1.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page2.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page3.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page4.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page5.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page6.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page7.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page8.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page9.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page10.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page11.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page12.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page13.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page14.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page15.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page16.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page17.tiff  
source=Patent Assignment (Coherus to HKF)\_Redacted#page18.tiff

## **PATENT ASSIGNMENT**

This PATENT ASSIGNMENT (this “Patent Assignment”) is entered into effective as of June 26, 2024, by and between COHERUS BIOSCIENCES, INC., a Delaware corporation (the “Assignor”), and HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD., a Hong Kong corporation (the “Assignee”, together with the Assignor, the “Parties”).

WHEREAS, the Assignor is the owner of all right, title and interest in, to and under the patents and patent applications described in the attached Schedule A (the “Patents”); and

WHEREAS, pursuant to the terms of that certain Asset Purchase Agreement (the “APA”), dated as of the date hereof, by and between the Assignor and the Assignee, the Assignor has agreed to convey, assign, and transfer to the Assignee the Patents and the Assignee has agreed to receive and accept the Patents.

NOW, THEREFORE, in furtherance of the APA and for good and valuable consideration as set forth in this Patent Assignment, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

1. Conveyance. The Assignor does hereby irrevocably sell, transfer, convey, assign and deliver to the Assignee (i) any and all rights, title, and interest throughout the world that the Assignor owns in the Patents set forth, or filed based on inventions and improvements claimed or described therein, the rights of priority thereto, any patent applications, patents, utility models or other similar registrations claiming priority or otherwise corresponding thereto, and any patent applications and/or patents otherwise related thereto (e.g., reexaminations, reissues, divisionals, continuations and continuations-in-part claiming priority from the aforesaid) that have been filed or will be filed in the United States (including its territories) and/or all foreign countries, together with all additions thereto, substitutions therefor and modifications thereof, and including the subject matter of all claims which may be obtained therefrom, all rights to collect royalties, products and proceeds in connection with any of the foregoing; and (ii) any and all rights, title and interest to sue for infringement of the Patents, including without limitation all right, title, and interest in and to all causes of action and enforcement rights, whether known, unknown, currently pending, filed, or otherwise, in respect of the Patents, and all rights to sue for and otherwise pursue and collect damages, injunctive relief, and other remedies for infringement of the Patents((i)-(ii) collectively the “Patent Rights”). This Patent Assignment includes any and all other rights arising from the Patent Rights under or pursuant to any and all international agreements, treaties, conventions, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and all rights to publish cautionary notices reserving ownership of the Patent Rights. Said Patent Rights are to be held and enjoyed by the Assignee for its own use and for its successors, assigns, and legal representatives, to the full end of the term for which said Patent Rights may be granted as fully and entirely as the same would have been held by the Assignor had this Patent Assignment and transfer not been made.

2. Recordation. The Assignor hereby requests that and authorizes the United States Patent and Trademark Office Commissioner for Patents and any other applicable governmental entity or registrar (including any applicable foreign or international office or registrar) to record the Assignee as the assignee and owner of the Patents in accordance with the terms of this Patent Assignment. The Assignor further authorizes the respective patent office or governmental agency in each other jurisdiction to issue any and all Patent Rights or certificates of invention that may be granted upon any of the Patents in the name of the Assignee, as the assignee to the entire interest therein.

3. Information and Assistance.

3.1 Upon the Assignee's reasonable request and without further compensation, the Assignor shall execute, acknowledge and deliver all such other instruments and documents and shall take all such other actions reasonably necessary or required by law to consummate and make fully effective the transaction contemplated by this Patent Assignment.

3.2 If the Assignee is unable for any reason to secure any of the Assignor's signatures to any document required to file, prosecute, register or memorialize the assignment of any rights under any Patents as provided under this Patent Assignment, the Assignor hereby irrevocably designates and appoints the Assignee and the Assignee's duly authorized officers and agents as the Assignor's agents and attorneys-in-fact to act for and on each of the Assignor's behalf and instead of the Assignor to take all lawfully permitted acts to further the filing, prosecution, registration, memorialization of assignment, and issuance of rights under such Patents, all with the same legal force and effect as if executed by the Assignor. The foregoing is deemed a power coupled with an interest and is irrevocable.

4. No Third-Party Beneficiaries. Nothing in this Patent Assignment, express or implied, is intended or shall be construed to confer upon, or to give to, any individual or entity other than the Assignee and its successors and assigns any remedy or claim under or by reason of this Patent Assignment or any terms, covenants or conditions hereof, and all the terms, covenants and conditions, promises and agreements in this Patent Assignment contained shall be for the sole and exclusive benefit of the Assignee and its successors and assigns.

5. Governing Law. This Patent Assignment, and all claims and causes of action arising out of, based upon, or related to this Patent Assignment or the negotiation, execution or performance hereof, shall be governed by, and construed, interpreted and enforced in accordance with, the Laws of the State of Delaware, without regard to choice or conflict of law principles that would result in the application of any Laws other than the Laws of the State of Delaware.

6. Successors and Assigns. This Patent Assignment and all of the provisions hereof shall be binding upon, inure to the benefit of and be enforceable by the Parties and their respective successors and assigns.

7. Counterparts. This Patent Assignment may be executed in two (2) counterparts, each of which shall be deemed an original but both of which together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each of the Parties

and delivered to the other Party, it being understood that both Parties need not sign the same counterpart. This Patent Assignment, to the extent signed and delivered by means of a photographic, photostatic, facsimile, portable document format (.pdf), or similar reproduction of such signed writing using a facsimile machine or electronic mail, shall be treated in all manner and respects as an original agreement and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

*[Signature page follows]*

**IN WITNESS WHEREOF**, the Parties have executed this Patent Assignment on the date first written above.

**ASSIGNEE:**

**HONG KONG KING-FRIEND  
INDUSTRIAL COMPANY LTD.**

DocuSigned by:  
By: Eric Tang  
Name: Eric Tang  
Title: CEO

**ASSIGNOR:**

**COHERUS BIOSCIENCES, INC.**

By: \_\_\_\_\_  
Name: Dennis M. Lanfear  
Title: CEO and President

**IN WITNESS WHEREOF**, the Parties have executed this Patent Assignment on the date first written above.


**ASSIGNEE:**

**HONG KONG KING-FRIEND  
INDUSTRIAL COMPANY LTD.**

By: \_\_\_\_\_  
Name:  
Title:

**ASSIGNOR:**

**COHERUS BIOSCIENCES, INC.**

By:  \_\_\_\_\_  
Name: Dennis M. Lanfear  
Title: CEO and President

**Schedule A**

**Patents**

*See attached.*

[Schedule A to Patent Assignment]

**PATENT**  
**REEL: 069084 FRAME: 0891**

# 1. Patents/Patent Applications





























| Title   | Filing Date | Appl. No.  | Publ. Date | Publ. No. | Issue Date | Patent No. | Country       | Inventors                       |            |
|---|-------------|------------|------------|-----------|------------|------------|---------------|---------------------------------|------------|
| METHODS FOR MAKING RECOMBINANT PROTEINS       | 9/4/2015    | 14/845,440 |            |           | 10/8/2019  | 10,435,464 | UNITED STATES | Elzbieta Wiktoria Puchacz       | ██████████ |
|   | 9/9/2019    | 16/564,642 |            |           | 7/26/2022  | 11,396,540 | UNITED STATES | Elzbieta Wiktoria Puchacz       | ██████████ |
|   | 6/16/2022   | 17/841,812 |            |           |            |            | UNITED STATES | Elzbieta Wiktoria Puchacz       | ██████████ |
|   | 10/28/2016  | 15/337,519 |            |           | 1/25/2022  | 11,229,702 | UNITED STATES | Mark Manning, Ryan Erik Holcomb | ██████████ |
|   | 1/24/2022   | 17/583,086 |            |           |            |            | UNITED STATES | Mark Manning, Ryan Erik Holcomb | ██████████ |
| HIGH CONCENTRATION FORMULATIONS OF ADALIMUMAB | 10/28/2015  | 62/247,348 |            |           |            |            | UNITED STATES | Mark Manning, Ryan Erik Holcomb | ██████████ |
|   | 10/26/2016  | 62/413,226 |            |           |            |            | UNITED STATES | None listed                     | ██████████ |





























































































PATENT






















































































REEL: 069084 FRAME: 0892




















































































| Title                                     | Filing Date | Appl. No.  | Publ. Date | Publ. No.          | Issue Date | Patent No. | Country       | Inventors                     |            |
|---|-------------|------------|------------|--------------------|------------|------------|---------------|-------------------------------|------------|
| STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB | 9/6/2013    | 14/020,733 | 7/3/2014   | US-2014-0186361-A1 |            |            | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
|   | 3/18/2015   | 14/661,288 | 7/9/2015   | US-2015-0190512-A1 | 5/17/2016  | 9,340,612  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
|   | 3/18/2015   | 14/661,899 | 7/9/2015   | US-2015-0191538-A1 | 5/24/2016  | 9,346,880  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
|   | 3/18/2015   | 14/661,938 | 7/9/2015   | US-2015-0191539-A1 | 7/5/2016   | 9,382,317  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
|   | 10/9/2015   | 14/879,847 | 2/11/2016  | US-2016-0039926-A1 | 8/8/2017   | 9,724,414  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |





















































































|            |            |            |                    |            |            |               |                               |            |
|------------|------------|------------|--------------------|------------|------------|---------------|-------------------------------|------------|
| 10/9/2015  | 14,879,885 | 2/4/2016   | US-2016-0031982-A1 | 11/7/2017  | 9,808,525  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 5/16/2016  | 15/155,832 | 9/8/2016   | US-2016-0256545-A1 | 6/20/2017  | 9,682,145  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 5/16/2016  | 15/155,982 | 9/8/2016   | US-2016-0256547-A1 | 10/17/2017 | 9,789,185  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 5/23/2016  | 15/162,140 | 9/15/2016  | US-2016-0263226-A1 | 9/12/2017  | 9,757,454  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 6/27/2016  | 15/193,345 | 10/20/2016 | US-2016-0304599-A1 | 9/26/2017  | 9,770,507  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 6/27/2016  | 15/193,387 | 6/27/2016  | US-2016-0304600-A1 | 8/15/2017  | 9,731,008  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 6/27/2016  | 15/193,415 | 10/20/2016 | US 2016-0304601 A1 | 8/22/2017  | 9,737,600  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 6/27/2016  | 15/193,454 | 10/20/2016 | US 2016-0303233 A1 | 10/10/2017 | 9,782,480  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 6/27/2016  | 15/193,486 | 10/20/2016 | US-2016-0303234-A1 | 8/8/2017   | 9,724,415  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 6/27/2016  | 15/193,523 | 10/20/2016 | US-2016-0303235-A1 | 8/15/2017  | 9,731,009  | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 7/18/2017  | 15/653,228 | 11/2/2017  | US-2017-0312361-A1 | 9/22/2020  | 10,780,163 | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 8/15/2017  | 15/677,857 | 1/25/2018  | US-2018-0021433-A1 | 9/29/2020  | 10,786,566 | UNITED STATES | Mark Manning, Robert W. Payne | ██████████ |
| 10/11/2017 | 15/730,399 | 2/1/2018   | US-2018-0028655-A1 |            |            | UNITED STATES | Mark Manning,                 | ██████████ |

|   |   |           |                        |   |   |   |   |   |
|---|---|-----------|------------------------|---|---|---|---|---|
|   |   |           |                        |   |   |   | Robert W.<br>Payne  |   |
| 10/11/2017  | 15/730,425  | 2/1/2018  | US-2018-<br>0028656-A1 |   |   | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |  |
| 10/11/2017  | 15/730,445  | 2/1/2018  | US-2018-<br>0028657-A1 |   |   | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |  |
| 6/29/2018   | 16/023,205  | 11/1/2018 | US-2018-<br>0311352-A1 | 6/23/2020   | 10,688,183  | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |  |
| 6/29/2018   | 16/023,161  | 11/1/2018 | US-2018-<br>0311351-A1 | 10/13/2020  | 10,799,585  | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |  |
| 6/29/2018   | 16/023,152  | 11/1/2018 | US-2018-<br>0311350-A1 | 9/15/2020   | 10,772,960  | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |    |
| 6/29/2018   | 16/023,046  | 11/1/2018 | US-2018-<br>0311349-A1 | 9/15/2020   | 10,772,959  | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |    |
| 11/1/2018   | 16/178,164  | 3/7/2019  | US-2019-<br>0070292-A1 | 7/21/2020   | 10,716,852  | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |    |
| 11/1/2018   | 16/178,309  | 3/7/2019  | US-2019-<br>0070293-A1 | 7/21/2020   | 10,716,853  | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |    |
| 11/1/2018   | 16/178,319  | 3/7/2019  | US-2019-<br>0070294-A1 | 7/21/2020   | 10,716,854  | UNITED<br>STATES  | Mark<br>Manning,<br>Robert W.<br>Payne  |    |
|  |  |           |                        |  |  |  |  |    |
|  |  |           |                        |  |  |  |  |    |
|  |  |           |                        |   |   |  |  |    |

|   |   |   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|   |   |   |   |   |   |   |   |   |   |   |   |   |
|    |    |    |    |    |    |    |    |    |    |    |    |    |
|    |    |    |    |    |    |    |    |    |    |    |    |    |
|    |   |    |   |   |   |   |    |   |   |   |   |   |
|    |   |    |   |    |   |   |    |   |   |   |   |   |
|  |  |   |  |  |  |  |   |  |  |  |  |   |
|  |  |   |  |  |  |  |   |  |  |  |  |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |



|   |   |   |   |   |   |   |  |   |   |   |   |   |
|---|---|---|---|---|---|---|--|---|---|---|---|---|
|   |   |   |   |   |   |   |  |   |   |   |   |   |
|    |    |    |    |    |    |    |     |    |    |    |    |   |
|    |    |    |    |    |    |    |     |    |    |    |    |   |
|   |   |   |   |    |    |   |  |   |   |   |    |   |
|   |   |   |   |   |   |   |  |   |   |   |   |   |
|   |  |  |  |   |  |  |   |  |  |  |   |   |
|   |  |  |  |   |  |  |   |  |  |  |   |   |
|  |  |  |  |  |  |  |   |  |  |  |  |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |   |  |  |  |  |   |

|   |   |   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|   |   |   |   |   |   |   |   |   |   |   |   |   |
|    |    |    |    |    |    |    |    |    |    |    |    |   |
|    |    |    |    |    |    |    |    |    |    |    |    |   |
|   |   |   |   |   |   |   |   |   |    |   |   |   |
|   |   |   |   |   |   |   |   |   |   |   |   |   |
|  |  |  |  |  |  |  |   |  |   |  |  |   |
|  |  |  |  |  |  |  |   |  |   |  |  |   |
|  |  |  |  |  |  |  |  |  |  |  |  |   |
|  |  |  |  |  |  |  |  |   |  |  |  |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |










|   |   |   |   |   |   |   |  |   |   |   |   |   |
|---|---|---|---|---|---|---|--|---|---|---|---|---|
|   |   |   |   |   |   |   |  |   |   |   |   |   |
|    |    |    |    |    |    |    |     |    |    |    |    |   |
|    |    |    |    |    |    |    |     |    |    |    |    |   |
|   |   |   |   |   |   |   |  |   |   |   |   |   |
|    |   |   |   |   |   |   |  |   |   |   |   |   |
|  |  |  |  |  |  |  |   |  |  |   |  |   |
|  |  |  |  |  |  |  |   |  |  |   |  |   |
|  |  |  |  |  |  |  |   |  |  |  |  |   |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |   |  |  |  |  |   |



|  |            |            |  |                    |           |               |  |  |  |
|--|------------|------------|--|--------------------|-----------|---------------|--|--|--|
| STABLE PROTEIN COMPOSITIONS AND METHODS OF THEIR USE |            |            |  |                    |           |               | Isaias Prado, Mark Manning   |  |  |
|  | 2/1/2017   | 62/453,370 |  |                    |           | UNITED STATES | John Ogez, Jun Liu, Wenchang Ji, Patrick Daniel Begley, Isaias Prado, Mark Manning |  |  |
|  |            |            |  |                    |           |               |  |  |  |
|  | 4/20/2017  | 15/492,999 |  | US-2017-0304445-A1 | 7/27/2021 | 11,071,782    | UNITED STATES  | John Ogez, Jun Liu, Wenchang Ji, Isaias Prado, Mark Manning, Patrick Daniel Begley |  |
|  | 10/28/2016 | 15/337,845 |  |                    |           | 11,583,584    | UNITED STATES  | Jun Liu, Mark Manning, Isaias Prado  |  |

| METHODS OF PRODUCING RECOMBINANT PROTEINS |            |  |  |  |  |               |   |   |
|---|------------|--|--|--|--|---------------|---|---|
| 9/8/2016                                  | 15/260,023 |  |  |  |  | UNITED STATES | Elzbieta Wiktoria Puchacz, Voker Sandig |  |
| 4/172019                                  | 16/387,353 |  |  |  |  | UNITED STATES | Elzbieta Wiktoria Puchacz, Voker Sandig |    |
| 7/23/2021                                 | 17/384,425 |  |  |  |  | UNITED STATES | Elzbieta Wiktoria Puchacz, Voker Sandig |    |

|  |            |            |  |  |  |  |               |  |   |
|--|------------|------------|--|--|--|--|---------------|--|---|
|  |            |            |  |  |  |  |               |  |   |
|  | 1/19/2024  | 18/417,110 |  |  |  |  | UNITED STATES | Elzbieta Wiktoria Puchacz, Voker Sandig  |  |
| A METHOD OF REDUCING IMMUNOGENICITY OF DRUG PRODUCTS | 10/25/2017 | 15/793,976 |  |  |  |  | UNITED STATES | John Ogez, Jun Liu, Wenchang Ji, Patrick Daniel Begley, Isaias Prado, Mark Manning |    |
| A METHOD OF FILLING A CONTAINER WITH NO HEADSPACE    | 10/28/2016 | 15/337,694 |  |  |  |  | UNITED STATES | John Ogez  |    |

| METHOD OF PRODUCING A RECOMBINANT PROTEIN   |   | STABLE PROTEIN<br>COMPOSITIONS AND<br>METHODS OF THEIR USE                            |
|---|---|---|
|    | 11/2/2021   | 7/1/2016  |
|    | 17/608,204  | 62/357,466  |
|    | 6/23/2022   |   |
|   | US-2022-<br>0195029-A1  |   |
|   |   |   |
|   |   |   |
|  | UNITED<br>STATES  | UNITED<br>STATES  |
|  | Robin<br>Modi,<br>James<br>Russell<br>Grove   | None<br>Listed  |
|  |  |  |

PATENT